Inovio

$12.44
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.87 (+18.00%) Today
+$0.18 (+1.47%) As of 5:00 PM EST after-hours

Why Robinhood?

You can buy or sell Inovio and other stocks, options, and ETFs commission-free!

About INO

Inovio Pharmaceuticals, Inc. Common Stock, also called Inovio, is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm's drug candidates include SynCon immunotherapies which helps break the immune system’s tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA. The listed name for INO is Inovio Pharmaceuticals, Inc. Common Stock.

CEO
J. Joseph Kim
Employees
194
Headquarters
Plymouth Meeting, Pennsylvania
Founded
1983
Market Cap
2.08B
Price-Earnings Ratio
Dividend Yield
Average Volume
12.06M
High Today
$12.40
Low Today
$10.50
Open Price
$10.50
Volume
21.18M
52 Week High
$33.79
52 Week Low
$2.28

Collections

INO Earnings

-$0.38
-$0.25
-$0.13
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 11, After Hours

You May Also Like